Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Santen Pharmaceutical CoSNPHF +4.40%71 Equity-to-Asset is 0.72 as of Jun. 2026, which is 3% below its 10-year median of 0.74. GuruFocus rates SNPHF with a GF Score™ of 71/100 and a GF Value™ of $11.96 (Modestly Overvalued). Among 1,005 Drug Manufacturers companies, Santen Pharmaceutical Co ranks better than 67.76% on this metric.
Santen Pharmaceutical Co (OTCPK:SNPHF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Santen Pharmaceutical Co Equity-to-Asset Related Terms
Santen Pharmaceutical Co Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SNPHF vs LLY, JNJ, ABBV: Equity-to-Asset Comparison
For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santen Pharmaceutical Co Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Santen Pharmaceutical Co's Equity-to-Asset falls into.
Santen Pharmaceutical Co Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Santen Pharmaceutical Co's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santen Pharmaceutical Co (SNPHF) has a Equity-to-Asset of 0.72 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Santen Pharmaceutical Co and its competitors. This is near median its historical median of 0.74. Over the past decade, Santen Pharmaceutical Co's Equity-to-Asset has ranged from 0.69 to 0.80. According to the industry distribution chart, Santen Pharmaceutical Co ranks #324 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 32.2%.
Is Santen Pharmaceutical Co's Equity-to-Asset too high?
Santen Pharmaceutical Co's current Equity-to-Asset of 0.72 is near median its 10-year median of 0.74. Over the past 10 years, this metric has ranged from a low of 0.69 to a high of 0.80. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Santen Pharmaceutical Co's value of 0.72 is 18% above this industry median. Based on the distribution chart, Santen Pharmaceutical Co ranks #324 out of 1005 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Santen Pharmaceutical Co has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Equity-to-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Santen Pharmaceutical Co ranks #324 out of 1005 companies for Equity-to-Asset. This puts Santen Pharmaceutical Co in the upper half of its industry. The industry median Equity-to-Asset is 0.61. Santen Pharmaceutical Co's value of 0.72 is 18% above this benchmark. Historically, Santen Pharmaceutical Co's own Equity-to-Asset has ranged from 0.69 to 0.80 over the past decade. While the company's 10-year median is 0.74 vs. the industry median of 0.61, Santen Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Santen Pharmaceutical Co's current Equity-to-Asset of 0.72 is 18% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Santen Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Santen Pharmaceutical Co's current Equity-to-Asset is 0.72, which is near median its own 10-year median of 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHF) is currently considered Modestly Overvalued. The stock's GF Value™ is $11.96, compared to a current price of $13.05 — trading 9.1% above its estimated fair value. The current Equity-to-Asset is 0.72, which is near median its 10-year median of 0.74 and 18% above the Drug Manufacturers industry median of 0.61. Santen Pharmaceutical Co's overall GF Score™ is 71/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHF), the current Equity-to-Asset is 0.72 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santen Pharmaceutical Co (SNPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued.
The current stock price of $13.05 is trading 9.1% above its estimated GF Value™ of $11.96.
GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SNPHF:
Equity-to-Asset: 0.72 (near median its 10-year median of 0.74)
GF Value™: $11.96 vs. price of $13.05 (9.1% above fair value)
Industry Position: 18% above the Drug Manufacturers median (#324 of 1005)
No single metric tells the full story. See the SNPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
71GF Score
Get the complete analysis for SNPHF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNPHF has been successfully added to your 
